Evidence map›Paper›PMID 36533934›Full record

ArticleAntimicrobial agents and chemotherapy2023

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia.

M Trang, J P Hammel, E A Lakota, M C Safir, S M Bhavnani, L Friedrich, J N Steenbergen, P C McGovern, E Tzanis, C M Rubino

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

M TrangInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.ORCID 0000-0002-3468-3343
J P HammelInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
E A LakotaInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
M C SafirInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.ORCID 0000-0003-0452-682X
S M BhavnaniInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.ORCID 0000-0003-4891-6467
L FriedrichParatek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
J N SteenbergenParatek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
P C McGovernParatek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
E TzanisParatek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
C M RubinoInstitute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.ORCID 0000-0003-3172-0847
Institute for Clinical Pharmacodynamics (United States) · USParatek Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Community-Acquired InfectionsPneumonia, BacterialAnti-Bacterial AgentsBacteriaHumansTetracyclinesAnti-Bacterial AgentsomadacyclineTetracyclinescommunity-acquired bacterial pneumoniaomadacyclinepharmacokinetics

Identifiers

PMID36533934
PMCPMC9872632
OpenAlexW4311931478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.